Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Outcomes of Refractory Cytomegalovirus Infection in the First Year after Allogeneic Hematopoietic Cell Transplantation

Transplantation and Cellular Therapy(2022)10.1016/j.jtct.2022.04.016Source: DataRank Database

Outcomes of Refractory Cytomegalovirus Infection in the First Year after Allogeneic Hematopoietic Cell Transplantation is a research paper published in Transplantation and Cellular Therapy (2022). On theSindex it has a DataRank of 0. It has been cited 10 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access10 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 1.32)OA: greenTopics (40)IDs (PubMed, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Phaedon D. Zavras ORCID,Yiqi Su ORCID,Jiaqi Fang,Roni Tamari ORCID,Christina Cho ORCID

Live enrichment

PubMed:35476955 OpenAlex:https://openalex.org/W4224882648

National Institutes of Health

Grant: 2P30CA008748-43

MOUSE GENETICS

National Institutes of Health

Grant: 5P01CA023766-14

MARROW TRANSPLANTATION IN LEUKEMIA AND OTHER DISEASES

NCI NIH HHS

Grant: P01 CA023766

NCI NIH HHS

Grant: P30 CA008748

FWCI

1.32

Citation Percentile

0.8%

Influential Citations

Citation Trend

2022

2023

2024

2025

2026

greenLicense: CC BY NC ND

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10243123/pdf/nihms-1811307.pdf

GREENhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10243123/pdf/nihms-1811307.pdf

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10243123/pdf/nihms-1811307.pdf

publisherhttps://api.elsevier.com/content/article/PII:S2666636722012398?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2666636722012398?httpAccept=text/plain

Fields of Study

Cytomegalovirus and herpesvirus researchParvovirus B19 Infection StudiesNeonatal Health and BiochemistryMedicine0301 basic medicine03 medical and health sciences0302 clinical medicineAntiviral AgentsCytomegalovirusCytomegalovirus InfectionsHematopoietic Stem Cell TransplantationHumansTransplant RecipientsViremia

MeSH Terms

Antiviral AgentsCytomegalovirus InfectionsCytomegalovirusHumansViremiaHematopoietic Stem Cell TransplantationTransplant Recipients

Keywords

MedicineHematopoietic cellInternal medicineHaematopoiesisBiologyStem cellCytomegalovirus InfectionsHematopoietic Stem Cell TransplantationCytomegalovirusHumansViremiaAntiviral AgentsTransplant RecipientsAllogeneic hematopoietic cell transplantationCMV end-organ diseaseHealthcare resource utilizationMortalityPreemptive therapyRefractory CMV

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being